New biopsy test may predict pancreatic tumor danger
NCT ID NCT06406387
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether checking for two proteins, ATRX and DAXX, in biopsy samples can help predict how aggressive non-functional pancreatic neuroendocrine tumors (NF-pNETs) are. Researchers will compare biopsy results with surgical tissue from 100 adults to see if the test can guide treatment decisions. The goal is to improve current grading methods and avoid underestimating tumor risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Verona
Verona, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do Younger-Age pancreatic tumors behave differently? a new study digs in
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Promising drug trial for rare pancreatic cancer stopped early
- Zapping pancreatic tumors without surgery: a safer approach?
- New PET scan agent aims to better detect rare tumors
- Custom mRNA vaccine takes on rare endocrine cancers